NCT05396300View on ClinicalTrials.gov

A Clinical Study of CEA-targeted CAR-T in the Treatment of CEA-positive Advanced Malignant Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 25, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2024

Conditions
Colorectal CancerEsophageal CancerStomach CancerPancreatic CancerMetastatic TumorRecurrent Cancer
Interventions
BIOLOGICAL

CEA CAR-T cells

Administration method: intravenous infusion or intraperitoneal injection； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (1)

310006

First affiliated hospital, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Chongqing Precision Biotech Co., Ltd

INDUSTRY

lead

Weijia Fang, MD

OTHER